CAMLs and EMT CTCs Improve Malignancy Detection in Lung Nodules

News related to:Creatv Bio, a Division of Creatv MicroTech, Inc · 2 min read

MONMOUTH JUNCTION, N.J., Nov. 17, 2026 /CourierPR/ -- ### Oncology, Precision Oncology 10:e2501142 in July 2026 is a double-blind study that evaluated the presence, type, or size of a biomarker called Cancer-Associated-Macrophage-Like Cells (CAMLs), as well as epithelial-mesenchymal transition circulating tumor cells (EMT CTCs) in patients with indeterminate pulmonary nodules. The study, which enrolled 203 patients with indeterminate nodules (0.8-3.0 cm) with no prior diagnosis of cancer, found that CAMLs were detected in 45% of all evaluable patient samples (n=191), while EMT CTCs were detected in 20%.

For the detection of patients with any malignancy, the positive predictive value (PPV) of CAMLs was 27.9%, and the negative predictive value (NPV) was 61.9%. The sensitivity of CAMLs was 37.5%, and the specificity was 51.2%. While CAMLs or EMT CTCs alone could not help to differentiate between benign and malignant indeterminate nodules, when CAMLs and EMT CTCs were present in conjunction, the results showed that specificity in identifying malignancy improved to 90.6%.

CAMLs are large (>50 microns) and polyploid cells that originate from the tumor site and are found circulating in the blood of patients with a variety of cancers, even in the earliest stages of disease. EMT CTCs are tumor cells found circulating in the blood of patients. Studies have shown that CAMLs and EMT CTCs have the potential to track cancer progression and therapy response and are particularly associated with disease progression.

The study, conducted by Creatv Bio, a Division of Creatv MicroTech, Inc., in collaboration with the Fox Chase Cancer Center and the University of Pennsylvania, aimed to determine if these biomarkers could help to identify the presence of malignancy in patients with unknown indeterminate lung nodules. The findings suggest that while CAMLs and EMT CTCs alone may not be sufficient for distinguishing between benign and malignant nodules, their presence together can significantly improve the specificity in identifying malignancy.

About Creatv Bio

Creatv Bio operates a CLIA-certified cancer diagnostics laboratory supporting its biopharmaceutical partners with research and investigational studies. Creatv's liquid biopsy test is an analytically validated assay for research and development and is not intended for clinical diagnosis, prognosis, treatment selection, or disease monitoring. For a technical presentation on the features of the CAML biomarker including clinical data, please contact Dan or Ron.

Start filing today

One press release free every week. No card required.

Create a free account